Clinical trial · Observational
Pharmacogenetic of Doxorubicin in HCC.
Pharmacogenetic of Doxorubicin in Patients With Hepatocellular Carcinoma: A Prospective Cohort Study
NCT06313047CI-TRIAL-00075506completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study included 81 HCC patients, both male and female. Prior to being assessed for eligibility, each recruited patient with HCC received a comprehensive review of their medical history, physical status, and laboratory results. Every research participant take part in the experiment and provided written informed consent.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Doxorubicin | Drug | Doxorubicin | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- HCC patients
- description
- Each of the patients was given Doxorubicin and followed up for one year.
- interventionNames
- Drug: Doxorubicin
Primary outcomes (2)
- measure
- GSTP1
- timeFrame
- 1 year
- description
- Genotyping
- measure
- CYP2B6
- timeFrame
- 1 year
- description
- Genotyping
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. When diagnosing the patient with HCC, the guidelines provided by the American Association for the Study of Liver Diseases (AASLD) were adhered to. 2. Be above 20 years old. 3. Individuals with intact organs. 4. There is no cure for HCC in surgery, microwave treatment, or radiofrequency ablation. Exclusion Criteria: 1. The patients refused to sign the formal consent. 2. Be more than 75 years old. 3. There is a notable case of portal vein thrombosis. 4. Spreads beyond the liver. 5. Encephalopathy of the liver. 6. Present sickness.
References
Publications (1)
- DERIVEDShilbayeh SAR, Abd El-Baset OA, Alshabeeb MA, Alanizi AH, Khedr NF, Werida RH. The Influence of CYP2B6, GSTP1, and SLCO1B1 Star Allele-Predicted Phenotypes and CBR1 Genetic Variants on Effectiveness Outcomes in Patients With Hepatocellular Carcinoma Receiving Doxorubicin via Transarterial Chemoembolization. Pharmacol Res Perspect. 2025 Jun;13(3):e70114. doi: 10.1002/prp2.70114. PMID 40405401